You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Suppliers and packagers for edluar


✉ Email this page to a colleague

« Back to Dashboard


edluar

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Viatris EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997 NDA Viatris Specialty LLC 0037-6010-93 5 BLISTER PACK in 1 CARTON (0037-6010-93) / 6 TABLET in 1 BLISTER PACK (0037-6010-35) 2009-07-24
Viatris EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997 NDA Viatris Specialty LLC 0037-6050-93 5 BLISTER PACK in 1 CARTON (0037-6050-93) / 6 TABLET in 1 BLISTER PACK (0037-6050-35) 2009-07-24
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Edluar

Introduction
Edluar, a brand name for the medication containing zolpidem tartrate, is a widely prescribed sleep aid belonging to the sedative-hypnotic class. Approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA), Edluar is primarily used for short-term treatment of insomnia. As a popular sleep aid, the demand for Edluar influences global supplier networks. This report provides a comprehensive overview of the key suppliers involved in the manufacturing, distribution, and distribution of Edluar, focusing on their roles, geographic locations, and market influence.

Understanding Edluar and Its Manufacturing Process
Edluar’s active pharmaceutical ingredient (API), zolpidem tartrate, is synthesized through advanced chemical processes requiring specialized facilities that meet Good Manufacturing Practice (GMP) standards. The compounding of the drug into sublingual tablets ensures rapid absorption, catering to acute sleep disturbances. Given its clinical importance, the supply chain comprises API producers, formulation specialists, and packaging entities.

Major API Suppliers for Edluar

1. Domestic Pharmaceutical Manufacturers
Several pharmaceutical giants in the United States and Europe manufacture and supply the API directly or through licensed partnerships. These include:

  • Takeda Pharmaceuticals: As the original developer of Edluar, Takeda maintains a vertically integrated supply chain that covers API production and final formulation. Their manufacturing plants, primarily in Japan and North America, ensure quality and supply stability.
  • Mitsubishi Tanabe Pharma Corporation: Collaborating with Takeda, Mitsubishi provides API manufacturing capabilities, prioritizing consistency and compliance with international standards.
  • Teva Pharmaceutical Industries: A global generic and branded drug manufacturer, Teva has the capacity to produce zolpidem tartrate API at scale, especially to meet global demand for sleep aids.

2. Contract Manufacturing Organizations (CMOs)
CMOs play a vital role in supplementing in-house production, often providing API synthesis or formulation services:

  • Hikal Ltd. (India): Known for custom synthesis of APIs, Hikal supplies zolpidem tartrate to various pharmaceutical companies worldwide, emphasizing cost-efficiency and regulatory compliance.
  • Siegfried AG (Switzerland): Provides development, manufacturing, and purification services for APIs, including compounds like zolpidem tartrate.

3. Asian API Producers
The global API market significantly depends on Asian manufacturers due to cost advantages and manufacturing capacity:

  • Shanghai-based Yangtze River Pharmaceutical Group: Engaged in API production, including sedatives, with extensive export capabilities.
  • Hanmi Pharmaceutical (South Korea): A research-driven firm with API manufacturing experience, supplying both domestic and international markets.

Distribution and Supply Chain Dynamics

1. Original Equipment Manufacturers (OEMs)
Original producers such as Takeda and Mitsubishi coordinate the entire supply process from API synthesis to critical documentation and quality assessments to ensure regulatory authorities’ approvals are maintained across jurisdictions.

2. Generic and Brand Market Distribution
Once approved, Edluar became available as a generic product, with other companies authorized under licensing agreements or through authorized generics. These companies source API from primary suppliers or CMOs. Their distribution networks span multiple geographies, including North America, Europe, and emerging markets in Asia and Latin America.

3. Regulatory Considerations
Regulatory authorities such as the U.S. FDA, EMA, and others impose strict standards on API manufacturing and distribution. Suppliers must demonstrate compliance with GMP, batch consistency, purity standards, and robust quality control measures. Regulatory approvals influence supply chain stability and market access.

Key Suppliers and Their Strategic Positions

Supplier Role Location Market Influence Notes
Takeda Pharmaceuticals Original API producer Japan High Maintains strategic control over Edluar API supply; ensures quality adherence
Mitsubishi Tanabe Pharma API manufacturing partner Japan High Critical in fulfilling global supply demands
Teva Pharmaceutical Industries API supplier and generic manufacturer Israel Major Supplies to global markets; scaling capacity based on demand
Hikal Ltd. Contract manufacturer India Growing Cost-effective API supplies; expanding manufacturing capacity
Yangtze River Pharmaceutical Group API producer China Significant Competitive pricing; large export operations

Future Outlook for Edluar Suppliers
The global sleep aid market faces evolving regulatory environments, rising competition from newer pharmacological agents, and increased demand for generics. Key suppliers are investing in capacity expansion, technological innovation, and quality improvements to sustain their market position. Supply chain resilience is gaining focus, especially amid geopolitical tensions and disruptions caused by the pandemic.

Conclusion
The supply of Edluar hinges on a network of dedicated API producers, formulation specialists, and distributors. Original manufacturers like Takeda and Mitsubishi play central roles, complemented by competitive Asian API suppliers such as Hikal and Yangtze River Pharmaceutical. Ensuring regulatory compliance, scaling production, and maintaining quality standards are critical to supply chain stability. As the demand for sleeping aids grows globally, these suppliers' strategic positioning will significantly influence Edluar’s availability and market competitiveness.


Key Takeaways

  • Edluar's supply chain relies heavily on both original and contract manufacturers, emphasizing quality, compliance, and capacity.
  • Takeda and Mitsubishi are primary API sources, owing to their direct involvement in Edluar’s development and manufacturing.
  • Asian API producers, notably China and India, provide cost-effective production options, increasingly essential for global supply coverage.
  • Regulatory adherence remains a critical factor influencing supplier credibility and distribution rights worldwide.
  • Ongoing capacity expansion and technological advancements by suppliers will shape the future stability and accessibility of Edluar.

Frequently Asked Questions (FAQs)

Last updated: July 30, 2025

1. Who are the leading API suppliers for Edluar?
Takeda Pharmaceuticals and Mitsubishi Tanabe Pharma are the primary originators and suppliers of zolpidem tartrate API. Additionally, contract manufacturers like Hikal and regional producers in China and South Korea supply the market.

2. How does regulatory compliance affect Edluar's supply chain?
Regulatory standards such as GMP compliance are mandatory for API production. Suppliers meeting these standards ensure uninterrupted supply and market access, while non-compliance can lead to manufacturing halts and recalls.

3. Are there alternatives to the original Edluar API suppliers?
Yes, several generic manufacturers and regional API producers can supply zolpidem tartrate, primarily from Asia, providing cost-effective alternatives without compromising quality when complying with international standards.

4. How is the global geopolitical landscape impacting Edluar suppliers?
Trade tensions, tariffs, and export restrictions, especially involving China and India, influence API access. Suppliers are diversifying production sites and building regional inventory buffers to mitigate risks.

5. What advancements are influencing future Edluar supply?
Investments in scalable synthesis technologies, improved purification methods, and supply chain digitalization are key trends ensuring future stability and quality of Edluar production.


References
[1] U.S. Food and Drug Administration (FDA). Edluar (zolpidem tartrate sublingual tablets) approval and regulatory documentation.
[2] Takeda Pharmaceuticals Annual Reports. Strategic manufacturing and supply overview.
[3] Market research reports on global API manufacturing capacity, 2022-2023.
[4] World Health Organization (WHO). Good Manufacturing Practice guidelines and compliance reports.
[5] Industry analyses on Asian API production trends and capacity expansions, 2022.


More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.